Abstract 451P
Background
Cancer anorexia-cachexia syndrome (CACS) can lead to impaired quality of life (QOL) and poor prognosis in advanced cancer patients. Anamorelin hydrochloride (anamorelin), an orally administered ghrelin-receptor agonist, has been approved in Japan among the first in the world for the treatment of CACS associated with advanced solid cancers including non-small cell lung cancer, gastrointestinal cancers, and pancreatic cancer. However, its efficacy and safety in clinical practice are not known well.
Methods
Unresectable non-small cell lung cancer patients treated with anamorelin were recruited in between 2021 July and 2022 December in a single institution in Japan. The characteristics of patient’s clinical background were investigated, and then the effects of anamorelin on body composition and appetite, and as well as the safety were evaluated in the real-world setting.
Results
In total, 73 patients were recruited in this study. The median age was 74 years. Fiyty-four were male, and nineteen were female. Clinical staging was as follows; 18, 37, 18 patients were at stage III, stage IV, and postoperative recurrence, respectively. ECOG performance status (PS) was; 1 in 49 cases, 2 in 19 cases, and 3 in 5 cases. The median BMI was 20.2 and the median degree of weight loss was -9.1% before anamorelin administration. Two thirds’ patients were prescribed anamorelin before 2nd-line treatment. Overall, there was a trend toward weight gain in 4 weeks after anamorelin administration. Improvement of appetite was observed in 54 patients (74.0%). These patients showed significantly better performance status, and more favorable treatment outcome and longer survival compared with ones who did not recover their appetite (p<0.05). Adverse events were observed in 20 patients (27.0%), 10 of which were hyperglycemia.
Conclusions
Anamorelin showed significant improvement of appetite in unresectable lung cancer patients with CACS. Earlier administration may bring out the favorable effects of anamorelin. Hyperglycemia should be noted as one of frequent adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract